[PBBANK] YoY TTM Result on 31-Mar-2016 [#1]

Announcement Date
20-Apr-2016
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2016
Quarter
31-Mar-2016 [#1]
Profit Trend
QoQ- 1.15%
YoY- 9.56%
View:
Show?
TTM Result
31/03/19 31/03/18 31/03/17 31/03/16 31/03/15 31/03/14 31/03/13 CAGR
Revenue 22,260,581 21,179,142 20,123,624 19,588,548 17,511,997 15,539,463 14,357,861 7.57%
PBT 7,126,466 7,280,159 6,533,946 6,654,275 5,975,833 5,367,108 5,085,812 5.78%
Tax -1,457,124 -1,575,744 -1,246,228 -1,472,178 -1,255,324 -1,213,357 -1,175,730 3.63%
NP 5,669,342 5,704,415 5,287,718 5,182,097 4,720,509 4,153,751 3,910,082 6.38%
-
NP to SH 5,595,324 5,627,434 5,225,066 5,120,423 4,673,417 4,113,314 3,864,873 6.35%
-
Tax Rate 20.45% 21.64% 19.07% 22.12% 21.01% 22.61% 23.12% -
Total Cost 16,591,239 15,474,727 14,835,906 14,406,451 12,791,488 11,385,712 10,447,779 8.00%
-
Net Worth 40,976,745 37,614,813 34,196,617 31,111,671 28,091,211 20,387,314 17,933,004 14.75%
Dividend
31/03/19 31/03/18 31/03/17 31/03/16 31/03/15 31/03/14 31/03/13 CAGR
Div 2,672,849 2,355,511 2,239,666 2,162,539 2,002,670 1,820,820 1,751,115 7.29%
Div Payout % 47.77% 41.86% 42.86% 42.23% 42.85% 44.27% 45.31% -
Equity
31/03/19 31/03/18 31/03/17 31/03/16 31/03/15 31/03/14 31/03/13 CAGR
Net Worth 40,976,745 37,614,813 34,196,617 31,111,671 28,091,211 20,387,314 17,933,004 14.75%
NOSH 3,882,138 3,882,138 3,882,138 3,882,138 3,882,138 3,501,831 3,501,992 1.73%
Ratio Analysis
31/03/19 31/03/18 31/03/17 31/03/16 31/03/15 31/03/14 31/03/13 CAGR
NP Margin 25.47% 26.93% 26.28% 26.45% 26.96% 26.73% 27.23% -
ROE 13.65% 14.96% 15.28% 16.46% 16.64% 20.18% 21.55% -
Per Share
31/03/19 31/03/18 31/03/17 31/03/16 31/03/15 31/03/14 31/03/13 CAGR
RPS 573.41 548.47 521.14 507.28 453.50 443.75 409.99 5.74%
EPS 144.13 145.73 135.31 132.60 121.03 117.46 110.36 4.54%
DPS 69.00 61.00 58.00 56.00 51.86 52.00 50.00 5.51%
NAPS 10.5552 9.741 8.8558 8.0569 7.2747 5.8219 5.1208 12.80%
Adjusted Per Share Value based on latest NOSH - 3,882,138
31/03/19 31/03/18 31/03/17 31/03/16 31/03/15 31/03/14 31/03/13 CAGR
RPS 114.65 109.08 103.64 100.89 90.19 80.03 73.95 7.57%
EPS 28.82 28.98 26.91 26.37 24.07 21.18 19.90 6.36%
DPS 13.77 12.13 11.53 11.14 10.31 9.38 9.02 7.30%
NAPS 2.1104 1.9372 1.7612 1.6023 1.4468 1.05 0.9236 14.75%
Price Multiplier on Financial Quarter End Date
31/03/19 31/03/18 31/03/17 31/03/16 31/03/15 31/03/14 31/03/13 CAGR
Date 29/03/19 30/03/18 31/03/17 31/03/16 31/03/15 31/03/14 29/03/13 -
Price 23.16 24.00 19.90 18.78 18.88 19.16 16.26 -
P/RPS 4.04 4.38 3.82 3.70 4.16 4.32 3.97 0.29%
P/EPS 16.07 16.47 14.71 14.16 15.60 16.31 14.73 1.46%
EY 6.22 6.07 6.80 7.06 6.41 6.13 6.79 -1.45%
DY 2.98 2.54 2.91 2.98 2.75 2.71 3.08 -0.54%
P/NAPS 2.19 2.46 2.25 2.33 2.60 3.29 3.18 -6.02%
Price Multiplier on Announcement Date
31/03/19 31/03/18 31/03/17 31/03/16 31/03/15 31/03/14 31/03/13 CAGR
Date 29/04/19 02/05/18 20/04/17 20/04/16 20/04/15 21/04/14 23/04/13 -
Price 22.56 24.00 19.92 19.02 19.60 20.20 16.34 -
P/RPS 3.93 4.38 3.82 3.75 4.32 4.55 3.99 -0.25%
P/EPS 15.65 16.47 14.72 14.34 16.19 17.20 14.81 0.92%
EY 6.39 6.07 6.79 6.97 6.17 5.81 6.75 -0.90%
DY 3.06 2.54 2.91 2.94 2.65 2.57 3.06 0.00%
P/NAPS 2.14 2.46 2.25 2.36 2.69 3.47 3.19 -6.43%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment